What are the common and serious side effects of pazopanib, and how should they be monitored and managed?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Pazopanib Side Effects and Management

Pazopanib causes serious and potentially life-threatening adverse effects that require intensive monitoring, with hepatotoxicity, hypertension, and cardiovascular toxicity being the most critical concerns requiring immediate intervention. 1

Serious/Life-Threatening Side Effects

Hepatotoxicity (Most Critical)

  • Elevated transaminases occur in up to 63.64% of patients, with severe liver injury requiring treatment interruption in >10% of cases 1, 2
  • Recent pharmacokinetic data identifies a critical threshold: trough concentrations >34 mg/L increase liver toxicity risk 3.35-fold 3
  • Monitor liver function tests within 1 week of starting therapy, then frequently during first months
  • If severe transaminase elevations occur, discontinue pazopanib immediately and consider stopping concurrent statins (pazopanib-simvastatin interaction significantly increases hepatotoxicity risk) 4

Hypertension

  • Occurs in 31.82-37% of patients, with sudden severe rises that can be life-threatening 1, 5, 2
  • Blood pressure increases typically manifest within the first several months of treatment 1
  • Check blood pressure within 1 week of starting pazopanib, then frequently throughout treatment
  • Ensure blood pressure is well-controlled before initiating therapy 1
  • Emergency symptoms requiring immediate medical attention: severe chest pain, severe headache, blurred vision, confusion, seizures, or loss of consciousness 1

Posterior Reversible Encephalopathy Syndrome (PRES)

  • Can cause death - presents with headaches, seizures, confusion, hypertension, vision changes, speech loss 1
  • Requires immediate treatment discontinuation

Cardiovascular Toxicity

  • QT interval prolongation and other cardiovascular events are well-documented 6
  • Mechanisms remain incompletely understood but warrant cardiac monitoring

Tumor Lysis Syndrome (TLS)

  • Can be fatal - caused by rapid cancer cell breakdown 1
  • Monitor for: irregular heartbeat, seizures, confusion, muscle cramps/spasms, decreased urine output
  • Requires blood test monitoring

Common Side Effects (Frequency Data)

Gastrointestinal

  • Diarrhea (31.82-33%) - most common overall 5, 2
  • Nausea/vomiting (18.18-34%) 5, 2
  • Anorexia/loss of appetite 1, 7
  • Stomach pain 1

Other Frequent Effects

  • Fatigue (27.27-51%) 8, 2
  • Hair color changes/depigmentation 1, 7
  • Hypertension (31.82-37%) 5, 2
  • Hypothyroidism (18.18%) - requires thyroid function monitoring 4, 2
  • Proteinuria (22.73%) - may require treatment discontinuation if severe 1, 2
  • Hand-foot skin reaction (22.73%) 2
  • Headache, taste changes, trouble breathing, skin color changes 1

Laboratory Abnormalities

  • Elevated transaminases (63.64%) 2
  • Leukopenia (13.64%) 2

Serious Infections

  • Can cause death 1
  • Monitor for: fever, persistent cold symptoms, flu symptoms, painful urination, infected wounds

Pneumothorax (Collapsed Lung)

  • Can occur with pazopanib - presents as sudden shortness of breath 1

Critical Drug Interactions

Avoid CYP3A4 inhibitors and inducers - pazopanib is primarily metabolized by CYP3A4 4, 7

  • Statins (especially simvastatin): significantly increase hepatotoxicity risk - consider discontinuation 4
  • Voriconazole, dexamethasone, prednisolone: alter pazopanib metabolism 4
  • Food effect: 2-fold increase in AUC with high-fat meals - take on empty stomach (1 hour before or 2 hours after meals) 7
  • Do not crush tablets - causes 2-fold AUC increase 7

Dose Modification Strategy

Recent evidence supports starting at 600 mg daily rather than the FDA-labeled 800 mg to reduce toxicity while maintaining efficacy 3:

  • Target therapeutic window: trough concentrations 20-34 mg/L
  • Treatment interruptions occur in 45% and dose reductions in 30% of patients 8
  • Real-world practice shows median starting doses of 300 mg daily (range 200-800 mg) with similar efficacy to full-dose trials 8

Comparative Toxicity Profile

Pazopanib shows higher rates of nausea, diarrhea, and hypertension compared to sorafenib and sunitinib, but significantly lower rates of hand-foot syndrome, rash, and mucositis compared to sorafenib 5. Sunitinib causes more severe mucositis (7.6% grade ≥3 vs 1.3% with pazopanib) 5.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.